Alexander Michels, Paul-Ehrlich-Institut, Langen, Germany, discusses the role of DARPin-targeted adeno-associated virus (DART-AAV) vectors in the development of chimeric antigen receptor (CAR)-T cell therapies. Standard AAV vectors are unable to carry out selective transduction, and a majority of studies in the CAR therapies utilize synthetic and lentiviral vectors. The advent of DART-AAV vectors enables directed evolution of the vectors themselves and are flexible in targeting various cell types including CD8 cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.